Celgene in $1 billion CAR-T deal with Juno

30 June 2015

US biotech major Celgene Corp (Nasdaq: CELG) has entered into a collaboration with fellow-USA-based and Juno Therapeutics (Nasdaq: JUNO) for the development and commercialization of immunotherapies. News of the deal sent Juno’s shares rocketing 37% to $63.50 in after-hours trading on Monday.

Under the terms of the 10-year agreement, Celgene will make an initial payment of around $1 billion which includes the purchase of about 9.1 million - or $ 846.3 million - shares of Juno stock at $93.00 per share, with the potential to increase its stake over time to as much as 30%.

The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on chimeric antigen receptor technology (CAR-T) and T cell receptor (TCR) technologies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK